Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Chonluten vs Crystagen — Peptide Comparison

At a Glance Quickcomparison Dose Range Chonluten 5–10 mg Crystagen 1–100 mcg/kg Frequency Once daily Administration Sublingual (enteric-coated capsules) Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Gradual (3-4 weeks) Evidence Level Lim

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Chonluten

5–10 mg

Crystagen

1–100 mcg/kg

Frequency

Once daily

Administration

Sublingual (enteric-coated capsules)

Subcutaneous injection

Cycle Length

12+ weeks

8-12 weeks

Onset Speed

Gradual (3-4 weeks)

Evidence Level

Limited human trials

Efficacy

Benefitratings

Respiratory Tissue Repair

Lung Inflammation Control

Age-Related Lung Protection

Immune Rejuvenation

Healthy Aging

Cancer Defense

Technical Data

Compoundspecifications

Molecular Formula

C11H17N3O8

Molecular Weight

319.27 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure

CAS Number

75007-24-8

C14H21N3O8

359.3 g/mol

Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids

Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure

Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Protocols

Dosingtiers

standard

5-10 mg

10-20 days per course

For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

1-2 capsules

1-2 times daily with meals

10-30 day course, repeated 2-3 times per year

The oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6]

200-400 mcg

10-20 days per course, repeated every 4-6 months

Can also be given as an intramuscular injection at a similar dose, used in research practice. [6]

1-2 capsules (10 mg each)

10-30 day course, repeated every 4-6 months

The oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]

Applications

Bestsuited for

Respiratory health restoration in aging individuals with declining lung function

Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Chronic bronchopulmonary conditions requiring tissue-level regenerative support

Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function

Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective therapy for lung tissue preservation in elderly populations

Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Restoring thymic function and immune competence in aging individuals with immune senescence

Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting immune function during and after illness recovery

Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Injection site reaction

Mild fatigue

Transient respiratory changes

Mild headache

Uncommon

Flu-like symptoms

Serious

No documented serious adverse effects

Minor digestive changes

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.

Contraindications

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)

xPregnancy and breastfeeding — insufficient reproductive safety data

xActive pulmonary infections requiring immediate medical treatment

xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)

xActive autoimmune disease in flare without physician supervision

xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Decision Guide

Which isright for you?

Choose Chonluten if...

Respiratory health restoration in aging individuals with declining lung function

Chronic bronchopulmonary conditions requiring tissue-level regenerative support

Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function

Geroprotective therapy for lung tissue preservation in elderly populations

Choose Crystagen if...

Restoring thymic function and immune competence in aging individuals with immune senescence

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Supporting immune function during and after illness recovery

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status FDA approved for this use Safety Overview Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible. Contraindications xKnown allergy to cetrorelix or any ingredient xPregnancy (it may harm the developing baby) xUndiagnosed vaginal bleeding xSevere liver or kidney disease xLatex allergy (some syringes contain latex) Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted. xPregnancy or suspected pregnancy xBreastfeeding xKnown allergies to any medication component xOvarian cysts larger than 3cm Decision Guide

Source: peptideinitiative.com ↗

Safety& evidence

FDA Status Research compound Safety Overview Testagen (lyophilized peptide complex) lacks published human safety data—all information derives from unpublished manufacturer data and theoretical extrapolation from rat studies. As an androgen secretagogue, it carries class risks including erythrocytosis (elevated red blood cell count), liver enzyme elevation, lipid profile unfavorable changes (reduced HDL, increased LDL), and prostate-related effects including urinary obstruction and potential malignancy acceleration. Cardiovascular risk including hypertension and increased thrombotic events are theoretical concerns based on androgen class pharmacology. Contraindications xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, glycine) xHormone-sensitive cancers (prostate, testicular) — potential stimulation of androgen-dependent pathways xPregnancy and breastfeeding (female partners) — not applicable for direct use but consider reproductive implications xSevere hepatic or renal impairment — peptide metabolism may be altered Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers. xKnown or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline) xSevere urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction xConcurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms Decision Guide

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

Vilon vs Crystagen — Peptide Comparison

At a Glance Quickcomparison Dose Range Vilon 5–10 mg Crystagen 1–100 mcg/kg Frequency Once daily Administration Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Gradual (3-4 weeks) Evidence…

Read guide →
03
Peptide Therapy Guide Editorial Team

Vesilute vs Prostamax — Peptide Comparison

At a Glance Quickcomparison Dose Range Vesilute 20–40 mg Prostamax 5–10 mg Frequency Once daily Administration Oral (capsule/tablet) Sublingual (enteric-coated capsules) Cycle Length 12+ weeks Onset Speed Grad…

Read guide →
04
Peptide Therapy Guide Editorial Team

Triptorelin vs Leuprolide — Peptide Comparison

At a Glance Quickcomparison Dose Range Triptorelin 0.1 mg–22.5 mg mg Leuprolide 3.75 mg–45 mg monthly or 3-month injections (depending on formulation) Frequency Once daily Administration Intramuscular injectio…

Read guide →